glp-1 and beta blockers Glucagon-like peptide-1 Current Insights, Advantages and Challenges

Dry mouth

Table 10: Results at Week 26 in a Trial Comparing TRESIBA U- 200 to Insulin Glargine U-100 in Adult Patients with Type 2 Diabetes Mellitus on OAD(s)* Study F TRESIBA Administered at the Same Time Each Day in Insulin Nave Adult Patients as an Add on to One or More of the Following Oral Agents Metformin, Sulfonylurea, Glinides or Alpha Glucosidase Inhibitors The efficacy of TRESIBA was evaluated in a 26 week randomized, open label, multicenter trial in Asia in 435 insulin nave patients with type 2 diabetes mellitus inadequately controlled on one or more oral antidiabetic agents (OADs) at baseline

2018;25(13):3564-3572.e4

CT scans: Better bone detail than X-rays